Previous close | 141.20 |
Open | 140.85 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 140.85 - 146.55 |
52-week range | 107.85 - 156.50 |
Volume | |
Avg. volume | 53,040 |
Market cap | N/A |
Beta (5Y monthly) | 1.03 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
IMCD_logo Logo IMCD Rotterdam, The Netherlands (26 April 2024) - IMCD N.V. (“IMCD” or “Company”), a global leading distribution partner, and formulator of speciality chemicals and ingredients, today announces its first three months 2024 results. HIGHLIGHTS Gross profit of EUR 295 million (on a constant currency basis, equal to the first three months of 2023)Operating EBITA decline of 15% to EUR 127 million (-13% on a constant currency basis)Free cash flow of EUR 106 million (first three months o
Photo_IMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma Photographed from left to right:•Cristina Marti, Director API Sales and Strategy, IMCD Group•Gianluca Galimberti, General Manager, Cobapharma•Tess Hendriks, Legal Counsel M&A, IMCD Group•Fenna van Zanten, Director M&A, IMCD Group•Jose Alcover, Managing Director, IMCD Iberia & Maghreb ROTTERDAM, The Netherlands 24 April 2024 – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and
Most readers would already know that IMCD's (AMS:IMCD) stock increased by 9.5% over the past three months. Given that...